Mohamed AbdElmoniem
Al Mansurah, 35516, Egypt
NCT Number: NCT07100821
Hemodynamic monitoring is measuring and monitoring the factors that influence the force and flow of the blood. It is an important aspect of patients care in operating rooms and critical care units. It aims to guide medical management so as to prevent or treat organ failure and improve the outcomes of patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Al Mansurah, 35516, Egypt
Hemodynamic monitoring is measuring and monitoring the factors that influence the force and flow of the blood. It is an important aspect of patients care in operating rooms and critical care units. It aims to guide medical management so as to prevent or treat organ failure and improve the outcomes of patients. This monitoring itself includes several different techniques and may range from invasive to less and even non-invasive techniques.
Critically ill patients are often hemodynamically unstable (or at risk of becoming unstable) owing to hypervolemia, cardiac dysfunction or alterations of vasomotor function, leading to organ dysfunction, deterioration into multi-organ failure and eventually death range from 15% to 25% of patients admitted to intensive care units.
Impedance cardiography (ICG) and Electrical Cardiometry (EC) are recently developed technologies to measure thoracic fluid content (TFC), cardiac output (CO) and other hemodynamic parameters. Both ICG and EC derive CO from measurements of Thoracic Electrical Bioimpedance (TEB).
One of the parameters examined by electrical cardiometry is thoracic fluid content(TFC) ,which is inversely associated with the patient's transthoracic electrical bioimpedance, and reflects the total (intravascular and extravascular) fluid volume contained in the chest cavity. A study concluded that electrical cardiometry monitoring indicated new possibility to anticipate prognosis of pneumonia patient. Increased thoracic fluid content value would relate to worse outcome of the patient like mortality and intensive care unit admission. Electrical cardiometry monitoring allows real-time measurements of thoracic fluid content without restraining the patient or invasive catheters.
In ARDS patients with cardiac comorbidities, TFC can distinguish between non-cardiogenic and cardiogenic pulmonary edema. In addition, TFC is helpful in the differential diagnosis of the mechanisms of respiratory failure. Thus, recently it was shown that TFC was greater in ARDS than in patients with atelectasis or pleural effusion. Therefore, depending on the TFC value, we can provide different therapeutic interventions.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Hemodynamic parameters was measured daily at 10 a.m by using ICON non-invasive cardiometer model C3 made in Germany by OSYPKA medical (figure 5) by placing the four sensors on the neck and left side of the thorax allow for the continuous measurement of the changes of electrical conductivity within the thorax parameters such as CO, TFC, SVV and FTC were calculated 3 times with 5-min intervals and stored on the device automatically.
Time frame: 6 months
Thoracic fluid content as an outcome predictor in length of stay in respiratory intensive care unit
Time frame: 6 months
Thoracic fluid content as an outcome predictor in duration of invasive mechanical ventilation
Time frame: 12 months
Thoracic fluid content and hemodynamic parameters measurement as an outcome predictor in mortality
Mansoura University Hospital
Other
Thoracic Fluid Content as an Outcome Predictor in Respiratory Intensive Care Unit
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06546839
Lung Cancer, Lung Cancer Metastatic
Istanbul, Bagcilar, Turkey (Türkiye)
View Trial DetailsNCT04227717
Bone Diseases, Central Nervous System Diseases
New York, United States
View Trial DetailsNCT06180148
Respiratory Tract Diseases, Thoracic Diseases
Moscow, Russia
View Trial DetailsNCT05411159
Nausea, Opioid Use
Beijing, Beijing Municipality, China
View Trial Details